Logo image of NVS

NOVARTIS AG-SPONSORED ADR (NVS) Stock Price, Quote, News and Overview

NYSE:NVS - New York Stock Exchange, Inc. - US66987V1098 - ADR - Currency: USD

109.35  +2.04 (+1.9%)

After market: 109.35 0 (0%)

NVS Quote, Performance and Key Statistics

NOVARTIS AG-SPONSORED ADR

NYSE:NVS (2/21/2025, 4:15:00 PM)

After market: 109.35 0 (0%)

109.35

+2.04 (+1.9%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week High120.92
52 Week Low92.35
Market Cap215.98B
Shares1.98B
Float1.72B
Yearly Dividend3.79
Dividend Yield3.58%
PE13.77
Fwd PE13.13
Earnings (Next)04-29 2025-04-29/bmo
IPO05-07 2001-05-07


NVS short term performance overview.The bars show the price performance of NVS in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 -5

NVS long term performance overview.The bars show the price performance of NVS in the last 1, 2 and 3 years. 1 year 2 years 3 years 5 10 15 20 25

The current stock price of NVS is 109.35 USD. In the past month the price increased by 9.31%. In the past year, price increased by 3.28%.

NOVARTIS AG-SPONSORED ADR / NVS Daily stock chart

NVS Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 67.21 829.40B
NVO NOVO-NORDISK A/S-SPONS ADR 27.53 390.99B
JNJ JOHNSON & JOHNSON 16.25 390.76B
AZN ASTRAZENECA PLC-SPONS ADR 20.56 230.14B
MRK MERCK & CO. INC. 11.71 226.40B
PFE PFIZER INC 8.46 149.04B
SNY SANOFI-ADR 13.61 136.49B
BMY BRISTOL-MYERS SQUIBB CO 48.97 113.23B
GSK GSK PLC-SPON ADR 7.81 74.77B
ZTS ZOETIS INC 27.1 72.39B
TAK TAKEDA PHARMACEUTIC-SP ADR 31.95 44.58B
RPRX ROYALTY PHARMA PLC- CL A 8.15 19.70B

About NVS

Company Profile

NVS logo image Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. The company is headquartered in Basel, Basel-Stadt and currently employs 76,057 full-time employees. The company went IPO on 2001-05-07. The firm develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The firm uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.

Company Info

NOVARTIS AG-SPONSORED ADR

Lichtstrasse 35

Basel BASEL-STADT CH 4056 CH

CEO: Vasant (Vas) Narasimhan

Employees: 76057

Company Website: https://www.novartis.com/

Investor Relations: https://www.novartis.com/investors

Phone: 41613241111

NOVARTIS AG-SPONSORED ADR / NVS FAQ

What is the stock price of NOVARTIS AG-SPONSORED ADR today?

The current stock price of NVS is 109.35 USD. The price increased by 1.9% in the last trading session.


What is the ticker symbol for NOVARTIS AG-SPONSORED ADR stock?

The exchange symbol of NOVARTIS AG-SPONSORED ADR is NVS and it is listed on the New York Stock Exchange, Inc. exchange.


On which exchange is NVS stock listed?

NVS stock is listed on the New York Stock Exchange, Inc. exchange.


What is the price forecast or stock price prediction for NOVARTIS AG-SPONSORED ADR stock?

30 analysts have analysed NVS and the average price target is 117.2 USD. This implies a price increase of 7.18% is expected in the next year compared to the current price of 109.35. Check the NOVARTIS AG-SPONSORED ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is NOVARTIS AG-SPONSORED ADR worth?

NOVARTIS AG-SPONSORED ADR (NVS) has a market capitalization of 215.98B USD. This makes NVS a Mega Cap stock.


How many employees does NOVARTIS AG-SPONSORED ADR have?

NOVARTIS AG-SPONSORED ADR (NVS) currently has 76057 employees.


What are the support and resistance levels for NOVARTIS AG-SPONSORED ADR (NVS) stock?

NOVARTIS AG-SPONSORED ADR (NVS) has a support level at 106.88 and a resistance level at 108.12. Check the full technical report for a detailed analysis of NVS support and resistance levels.


Is NOVARTIS AG-SPONSORED ADR (NVS) expected to grow?

The Revenue of NOVARTIS AG-SPONSORED ADR (NVS) is expected to grow by 4.08% in the next year. Check the estimates tab for more information on the NVS EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy NOVARTIS AG-SPONSORED ADR (NVS) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does NOVARTIS AG-SPONSORED ADR (NVS) stock pay dividends?

NOVARTIS AG-SPONSORED ADR (NVS) has a dividend yield of 3.58%. The yearly dividend amount is currently 3.79. Check the full fundamental report for a detailed analysis of NVS dividend history, reliability and sustainability.


When does NOVARTIS AG-SPONSORED ADR (NVS) report earnings?

NOVARTIS AG-SPONSORED ADR (NVS) will report earnings on 2025-04-29, before the market open.


What is the Price/Earnings (PE) ratio of NOVARTIS AG-SPONSORED ADR (NVS)?

The PE ratio for NOVARTIS AG-SPONSORED ADR (NVS) is 13.77. This is based on the reported non-GAAP earnings per share of 7.94 and the current share price of 109.35 USD. Check the full fundamental report for a full analysis of the valuation metrics for NVS.


What is the Short Interest ratio of NOVARTIS AG-SPONSORED ADR (NVS) stock?

The outstanding short interest for NOVARTIS AG-SPONSORED ADR (NVS) is 0.24% of its float. Check the ownership tab for more information on the NVS short interest.


NVS Technical Analysis

ChartMill assigns a technical rating of 7 / 10 to NVS. When comparing the yearly performance of all stocks, NVS turns out to be only a medium performer in the overall market: it outperformed 53.38% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

NVS Fundamental Analysis

ChartMill assigns a fundamental rating of 7 / 10 to NVS. NVS scores excellent points on both the profitability and health parts. This is a solid base for a good stock.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

NVS Financial Highlights

Over the last trailing twelve months NVS reported a non-GAAP Earnings per Share(EPS) of 7.94. The EPS increased by 13.19% compared to the year before.


Industry RankSector Rank
PM (TTM) 23.09%
ROA 12.25%
ROE 28.61%
Debt/Equity 0.51
Chartmill High Growth Momentum
EPS Q2Q%29.41%
Sales Q2Q%15.14%
EPS 1Y (TTM)13.19%
Revenue 1Y (TTM)-13.61%

NVS Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 70% to NVS. The Buy consensus is the average rating of analysts ratings from 30 analysts.

For the next year, analysts expect an EPS growth of 4.9% and a revenue growth 4.08% for NVS


Ownership
Inst Owners39.02%
Ins Owners0.01%
Short Float %0.24%
Short Ratio2.54
Analysts
Analysts70
Price Target117.2 (7.18%)
EPS Next Y4.9%
Revenue Next Year4.08%